ReviewFrontiers in neuroscience2018
Circulating miRNAs as Diagnostic Biomarkers for Parkinson's Disease.
Review in Frontiers in neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Photonic and nanomaterial-driven optical biosensing strategies for Parkinson's disease.Mikrochimica acta · 2026Review
- Mitochondria-Associated MicroRNAs: Emerging Roles in the Pathogenesis of Parkinson's Disease.Biomedicines · 2026Review
- Retrospective longitudinal analysis of blood microRNA-7-5p as a possible progression biomarker in people with Parkinson's disease.Frontiers in neuroscience · 2026Article
- Modulation of Behavioral, Biochemical, Immunomodulatory, and Transcriptional Profiles by the StrainInternational journal of molecular sciences · 2025Article
- An Exploratory Analysis of Differential Tear Fluid miRNAs in Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.Molecular neurobiology · 2025Article
- Distinct microRNA signatures define sporadic PSP-RS and PD in patient-derived midbrain organoids.iScience · 2025Article
- New Insights on the Potential Role of Pyroptosis in Parkinson's Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics.Molecular neurobiology · 2025Review
- CircPRDM5-mediated regulation of miR-433-3p and HDAC6 in Parkinson's disease: a novel neuroprotective axis.Journal of translational medicine · 2025Article
- MicroRNAs Fine-Tune Brain and Body Communication in Health and Disease : MicroRNAs in Brain-Body Communication.Advances in experimental medicine and biology · 2025Review
- Distribution of microRNA Counts Across Human Chromosomes.Current medicinal chemistry · 2025Article
- Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson's Disease.International journal of molecular sciences · 2024Review
- Cohort-specific boolean models highlight different regulatory modules during Parkinson's disease progression.iScience · 2024Article
- Exploring circular RNAs as biomarkers for Parkinson's disease and their expression changes after aerobic exercise rehabilitation.Functional & integrative genomics · 2024Review
- Role of microRNAs in cognitive decline related to COVID‑19 (Review).Experimental and therapeutic medicine · 2024Review
- MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.Frontiers in molecular neuroscience · 2024Review
- Exploring Various Transfection Approaches and Their Applications in Studying the Regenerative Potential of Dental Pulp Stem Cells.Current issues in molecular biology · 2023Review
- Adaptation Response in Sheep: Ewes in Different Cortisol Clusters Reveal Changes in the Expression of Salivary miRNAs.Animals : an open access journal from MDPI · 2023Article
- Data Mining of Microarray Datasets in Translational Neuroscience.Brain sciences · 2023Review
- Research progress on the role of extracellular vesicles in neurodegenerative diseases.Translational neurodegeneration · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Its main neuropathological hallmarks are the degeneration of dopaminergic neurons in the substantia nigra and alpha-synuclein containing protein inclusions, called Lewy Bodies. The diagnosis of idiopathic PD is still based on the assessment of clinical criteria, leading to an insufficient diagnostic accuracy. Additionally, there is no biomarker available allowing the prediction of the disease course or monitoring the response to therapeutic approaches. So far, protein biomarker candidates such as alpha-synuclein have failed to improve diagnosis of PD. Circulating microRNAs (miRNAs) in body fluids are promising biomarker candidates for PD, as they are easily accessible by non- or minimally-invasive procedures and changes in their expression are associated with pathophysiological processes relevant for PD. Advances in miRNA analysis methods resulted in numerous recent publications on miRNAs as putative biomarkers. Here, we discuss the applicability of different body fluids as sources for miRNA biomarkers, highlight technical aspects of miRNA analysis and give an overview on published studies investigating circulating miRNAs as biomarker candidates for diagnosis of PD and other Parkinsonian syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.